Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-08-26
2002-10-15
Priebe, Scott D. (Department: 1632)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S252330, C435S320100, C435S325000, C536S023100, C536S023500, C536S023400
Reexamination Certificate
active
06465211
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate, to a gene encoding the polypeptide, to a recombinant vector including the gene, to a transformant including the vector and to a method for producing the high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate.
BACKGROUND OF THE INVENTION
Inositol 1,4,5-trisphosphate (hereinafter, also referred to as “IP
3
”) is one of second messengers which are produced by inositol phospholipid metabolism activated in response to an extracellular stimului such as hormones, growth factors, neurotransmitters or the like. IP
3
is a substance that induces the increase of intracellular calcium concentration. The IP
3
-induced calcium increase is a crucial and highly universal signal transmission mechanism that is involved in many cell functions in a wide variety of animals. For example, IP
3
controls many physiological functions such as fertilization, blastogenesis, development and differentiation, cell growth, secretion, immune system, muscle contraction, and cranial nerve functions (gustation, vision, memory, learning, etc.) in diverse organisms, for example, invertebrate such as nematoda (nemathelminthes), Drosophila (arthropoda) and cuttlefish (mollusca), and vertebrata such as mouse and human.
On the molecular level, this mechanism is initiated by the binding between an IP
3
and its target, an IP
3
receptor. Specifically, when the IP
3
binds to the IP
3
receptor (a calcium channel susceptible to IP
3
) present in an intracellular calcium-storing site (endoplasmic reticulum, etc.), the channel opens and releases calcium from the calcium-storing site into the cytoplasm, thereby controlling the activities of calcium-dependent proteins and enzymes.
Heparin, adenophostin (a kind of fungal metabolite) and Xestospongin (a kind of sponge metablite) are examples of substances that might affect the signal transmission by the IP
3
-induced calcium. However, although heparin inhibits the binding between the IP
3
and the IP
3
receptor, its specificity is low since there are various targets in the cell. Adenophostin is an antagonistic agonist of the binding between the IP
3
and the IP
3
receptor, and is a powerful activator of the IP
3
receptor channel. However, its use is limited since its yield from fungus is low and it cannot transport across the membrane. Xestospongin has recently been reported as an inhibitor of the IP
3
receptor channel that does not influence the binding of IP
3
. Again, its yield is low and there are still questions remaining as to its specificity. Thus, currently, there is almost no substance that is considered to effectively act on IP
3
-induced calcium signal transmission. In particular, there has been no substance or system that inhibits IP
3
-induced calcium signal transmission by specifically trapping IP
3
that has increased on the cell level.
SUMMARY OF THE INVENTION
The present invention provides a high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate, a gene encoding the polypeptide, a recombinant vector containing the gene, a transformant containing the vector and a method for producing the high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate.
In order to solve the above-described problem, the present inventors have gone through intensive studies and have succeeded in isolating a high affinity polypeptide having an extremely high binding activity to IP
3
from a protein including a part of the N-terminal amino acid region of an IP
3
receptor.
The present invention provides a recombinant polypeptide of the following (a), (b) or (c):
(a) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2;
(b) a polypeptide comprising an amino acid sequence having deletion, substitution or addition of at least one amino acid in the amino acid sequence shown in SEQ ID NO: 2, and having a high affinity binding activity to inositol 1,4,5-trisphosphate; or
(c) a polypeptide having at least 70% homology with the amino acid sequence shown in SEQ ID NO: 2, and having a high affinity binding activity with inositol 1,4,5-trisphosphate.
The present invention also provides a gene coding for a polypeptide of the above (a), (b) or (c); or a gene coding for a polypeptide having at least 70% homology with the gene and having a high affinity binding activity with inositol 1,4,5-trisphosphate.
The present invention further provides a gene comprising DNA of the following (d) or (e):
(d) DNA of a nucleotide sequence shown in SEQ ID NO: 1; or
(e) DNA of a nucleotide sequence having at least 70% homology with the DNA of the nucleotide sequence shown in SEQ ID NO: 1, and coding for a polypeptide having a high affinity binding activity with inositol 1,4,5-trisphosphate.
The present invention provides a recombinant vector comprising any one of the above-described genes.
The present invention also provides a transformant comprising the above recombinant vector.
The present invention further provides a method for producing any one of the above-mentioned polypeptides, the method comprising: culturing the above-mentioned transformant; and collecting, from the obtained culture, a polypeptide having a high affinity binding activity to inositol 1,4,5-trisphosphate.
This and other advantages of the present invention will become apparent to those skilled in the art upon reading and understanding the following detailed description with reference to the accompanying figures.
This specification includes part or all of the contents as disclosed in the specification and/or drawings of Japanese Patent Application No. 10-242207 which is a priority document of the present invention.
REFERENCES:
patent: 08245698 (1996-09-01), None
patent: WO 96/00586 (1996-01-01), None
patent: WO96/24846 (1996-08-01), None
Crystal R., “Transfer of genes to humans: Early lessons and obstacles to success.” Science, vol. 270: 404-410, 1995.*
Deonarain M., “Ligand-targeted receptor-mediated vectors for gene delivery.” Exp. Opin. Ther. Patents, vol. 8 (1): 53-69, 1998.*
Eck et al., “Gene-based therapy.” Goodman & Gilman's The Pharmacological Basis of Therapeutics- Ninth Edition, McGraw-Hill: 77-101, 1996.*
Verma et al., “Gene therapy—promises, problems, and prospects”. Nature, vol. 389: 239-242, Sep. 1997.*
Miller et al., “Targeted vectors for gene therapy.” FASEB Journal, vol. 9: 190-199, Feb. 1995.*
Blau et al., “Molecular Medicine, Gene therapy—A Novel Form of Drug Delivery”. The New England Journal of Medicine, vol. 333 (18): 1204-1207, Nov. 1995.*
Anderson FW, “Human gene therapy”. Nature, vol. 392 (SUPP): 25-30, Apr. 1998.*
Frommel et al., “An estimate on the effect of point mutation and natural selection on the rate of amino acid replacement in proteins”. Journal of Molecular Evolution, vol. 21: 233-257, 1985.*
Ngo et al., “Computational Complexity, protein structure prediction, and the Levinthal Paradox”. The protein folding problem and tertiary structure prediction: 492-495, 1994.*
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions”. Science, vol. 247: 1306-1310, Mar. 1990.*
Harnick et al., “The Human Type I Inositol 1, 4, 5-trisphosphate Receptor from T Lymphocytes”. Journal of Biol. Chem., vol. 270 (6): 2833-2840, Feb. 1995.*
Furuichi et al., “Nucleotide Sequence of cDNA encoding P400 protein in the mouse cerebellum”. Nucleic Acid Res., vol. 17 (13): 5385-5386, 1989.*
Mignery et al., “Structure and Expression of the Rat Inositol 1, 4, 5-trisphosphate Receptor”. Journal of Biol. Chem., vol. 265 (21): 12679-12685, Sep. 1997.*
Yamada et al., “Human Inositol 1, 4, 5-trisphosphate type-1 receptor, InsP3R1: structure, function, regulation of expression and chromosomal localization”. Biochem. J., vol. 302: 781-790, 1994.*
Yoshikawa et al.; High Efficient Expression of the Functional Ligand Binding Site of the Inositol 1,4,5-Trisphosphate Receptor inEscherichia coli, 1999, Biochemical and Biophysical Research Comm.: 792-797.*
Newton et
Furuichi Teiichi
Mikoshiba Katsuhiko
Uchiyama Tsuyoshi
Yoshikawa Fumio
Fish & Richardson P.C.
Priebe Scott D.
Riken
LandOfFree
Nucleic acids, vectors and transformed cells for making and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids, vectors and transformed cells for making and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids, vectors and transformed cells for making and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2934736